Scarica l'app Stockscreener
26.58
1.04%
-0.28
Dopo l'orario di chiusura:
26.64
0.06
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$26.86
Aprire:
$27.02
Volume 24 ore:
34.23M
Relative Volume:
0.73
Capitalizzazione di mercato:
$151.14B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
19.61
EPS:
1.3551
Flusso di cassa netto:
$9.08B
1 W Prestazione:
-1.74%
1M Prestazione:
-3.63%
6M Prestazione:
+11.35%
1 anno Prestazione:
+3.83%
Intervallo 1D:
$26.57
$27.28
Intervallo di 1 settimana:
$26.36
$27.41
Portata 52W:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.58 | 151.14B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
China Obesity Approval Puts Pfizer’s GLP 1 Bet In Sharper Focus - simplywall.st
Pfizer (PFE) Quietly Arms Pipeline for Next Growth Wave - TipRanks
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation - Seeking Alpha
Market Watch Rx: Pfizer Joins Top Gainers - Pharmaceutical Executive
Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch - TipRanks
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart.com
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance Singapore
Pfizer's Top Legal Officer Nets Almost $2.3M More In 2025 - Law360
Lobbying Update: $2,870,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Self-represented worker’s 64-page Pfizer claim struck for violating pleading rules - HR Law Canada
CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review - Pfizer
Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline - TipRanks
How Investors Are Reacting To Pfizer (PFE) Phase 2 Win For Tilrekimig In Atopic Dermatitis - simplywall.st
Form DEF 14A PFIZER INC For: Apr 23 - StreetInsider
The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income - Barchart.com
Franklin Resources Inc. Raises Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Mackenzie Financial Corp Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Capital World Investors Purchases 286,493 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer’s Weight Management Drug Wins China Approval - Insider Monkey
Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case - Reuters
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Pfizer streamlines LC/UV/MS data processing, analysis and reporting - Chromatography Today
Improving method transfer: How Pfizer uses method development software - Chromatography Today
Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study - TipRanks
Dilated Cardiomyopathy Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Bristol Myers Squibb, Berlin Cures, Cumberland Pharma, Vericel Corp, Corimmun GmbH, Pfizer, Constant Therapeut - Barchart.com
One Pediatric Gastroenterologist’s Mission to Expand Pediatric Treatment Options - Pfizer
651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA - MarketBeat
Nasal Vaccines Market Is Going to Boom Rapidly | Pfizer • Moderna • GlaxoSmithKline - openPR.com
Richard Bernstein Advisors LLC Has $1.33 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc.: No turn-around in sight - marketscreener.com
Pfizer Stock: Cheap For A Reason (NYSE:PFE) - Seeking Alpha
Pfizer’s Comirnaty update: what the new COVID shot really means for you - AD HOC NEWS
Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns - Yahoo Finance
Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Self -Care for Caregivers - Pfizer
PFIZER INC : UBS is Neutral - marketscreener.com
GIPR antagonists reported in Pfizer patent - bioworld.com
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity - FinancialContent
Van ECK Associates Corp Sells 4,744,499 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE): Impact from BioNTech Partnership in 2026 - GuruFocus
Legal & General Group Plc Purchases 3,296,415 Shares of Pfizer Inc. $PFE - MarketBeat
Banque Cantonale Vaudoise Sells 92,252 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
Pfizer Leans On Obesity And Immunology To Refresh Growth Story - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):